135 related articles for article (PubMed ID: 18593770)
41. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly.
Gatto F; Feelders RA; van der Pas R; Kros JM; Waaijers M; Sprij-Mooij D; Neggers SJ; van der Lelij AJ; Minuto F; Lamberts SW; de Herder WW; Ferone D; Hofland LJ
J Clin Endocrinol Metab; 2013 Jan; 98(1):E66-71. PubMed ID: 23118420
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of 48 weeks of treatment with octreotide LAR in newly diagnosed acromegalic patients with macroadenomas: an open-label, multicenter, non-comparative study.
Grottoli S; Celleno R; Gasco V; Pivonello R; Caramella D; Barreca A; Ragazzoni F; Pigliaru F; Alberti D; Ferrara R; Angeletti G
J Endocrinol Invest; 2005 Dec; 28(11):978-83. PubMed ID: 16483175
[TBL] [Abstract][Full Text] [Related]
43. [Evaluation of the efficacy of long-acting somatostatin analog as adjunctive therapy in patients with active acromegaly].
Gołkowski F; Buziak-Bereza M; Huszno B
Przegl Lek; 2006; 63(3):117-22. PubMed ID: 16967698
[TBL] [Abstract][Full Text] [Related]
44. Investigation into the efficacy and safety of octreotide LAR in Japanese patients with acromegaly: Shizuoka study.
Oki Y; Inoue T; Imura M; Tanaka T; Genma R; Iwabuchi M; Hataya Y; Matsuzawa Y; Iino K; Nishizawa S; Nakamura H
Endocr J; 2009; 56(9):1095-101. PubMed ID: 19755754
[TBL] [Abstract][Full Text] [Related]
45. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
Laczi F; Magony S; Julesz J
Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
[TBL] [Abstract][Full Text] [Related]
46. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.
Caron PJ; Bevan JS; Petersenn S; Flanagan D; Tabarin A; Prévost G; Maisonobe P; Clermont A;
J Clin Endocrinol Metab; 2014 Apr; 99(4):1282-90. PubMed ID: 24423301
[TBL] [Abstract][Full Text] [Related]
47. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR.
Taboada GF; Luque RM; Neto LV; Machado Ede O; Sbaffi BC; Domingues RC; Marcondes JB; Chimelli LM; Fontes R; Niemeyer P; de Carvalho DP; Kineman RD; Gadelha MR
Eur J Endocrinol; 2008 Mar; 158(3):295-303. PubMed ID: 18299461
[TBL] [Abstract][Full Text] [Related]
48. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
Plöckinger U; Quabbe HJ
Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
[TBL] [Abstract][Full Text] [Related]
49. Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review.
Kurahashi K; Endo I; Kondo T; Morimoto K; Yoshida S; Kuroda A; Aihara KI; Matsuhisa M; Nakajima K; Mizobuchi Y; Nagahiro S; Abe M; Fukumoto S
Intern Med; 2017 Sep; 56(18):2455-2461. PubMed ID: 28824054
[TBL] [Abstract][Full Text] [Related]
50. Somatotropinomas inadequately controlled with octreotide may over-respond to pasireotide: the importance of dose adjustment to achieve long-term biochemical control.
Shimon I; Saeger W; Wildemberg LE; Gadelha MR
Hormones (Athens); 2017 Jan; 16(1):84-91. PubMed ID: 28500831
[TBL] [Abstract][Full Text] [Related]
51. Disappearance of a GH secreting macroadenoma, during long-term somatostatin analogue administration.
Ozbek M; Erdogan M; Akbal E; Gönülalan G
Exp Clin Endocrinol Diabetes; 2009 Jul; 117(7):309-11. PubMed ID: 18841538
[TBL] [Abstract][Full Text] [Related]
52. Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR).
Stewart PM; Stewart SE; Clark PM; Sheppard MC
Clin Endocrinol (Oxf); 1999 Mar; 50(3):295-9. PubMed ID: 10435053
[TBL] [Abstract][Full Text] [Related]
53. Primary octreotide LAR therapy in GH-secreting pituitary adenoma.
Harinarayan CV
J Indian Med Assoc; 2004 May; 102(5):258, 260-1. PubMed ID: 15636029
[TBL] [Abstract][Full Text] [Related]
54. Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly.
Colao A; Auriemma RS; Rebora A; Galdiero M; Resmini E; Minuto F; Lombardi G; Pivonello R; Ferone D
Clin Endocrinol (Oxf); 2009 Aug; 71(2):237-45. PubMed ID: 19094074
[TBL] [Abstract][Full Text] [Related]
55. Pituitary tumor disappearance in a patient with newly diagnosed acromegaly primarily treated with octreotide LAR.
Resmini E; Murialdo G; Giusti M; Boschetti M; Minuto F; Ferone D
J Endocrinol Invest; 2005 Feb; 28(2):166-9. PubMed ID: 15887864
[TBL] [Abstract][Full Text] [Related]
56. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
Caron P; Arlot S; Bauters C; Chanson P; Kuhn JM; Pugeat M; Marechaud R; Teutsch C; Vidal E; Sassano P
J Clin Endocrinol Metab; 2001 Jun; 86(6):2849-53. PubMed ID: 11397898
[TBL] [Abstract][Full Text] [Related]
57. The efficacy of octreotide LAR (long acting release) treatment in patients with somatotropinoma, and mixed pituitary tumours.
Waśko R; Bolko P; Owecki M; Jaskuła M; Sowiński J
Pharm World Sci; 2004 Dec; 26(6):324-7. PubMed ID: 15683101
[TBL] [Abstract][Full Text] [Related]
58. Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR.
Lundin P; Edén Engström B; Karlsson FA; Burman P
AJNR Am J Neuroradiol; 1997 Apr; 18(4):765-72. PubMed ID: 9127047
[TBL] [Abstract][Full Text] [Related]
59. The treatment of de novo acromegalic patients with octreotide-LAR: efficacy, tolerability and cardiovascular effects.
Gilbert J; Ketchen M; Kane P; Mason T; Baister E; Monaghan M; Barr S; Harris PE
Pituitary; 2003; 6(1):11-8. PubMed ID: 14674719
[TBL] [Abstract][Full Text] [Related]
60. Control of disease activity and tumor size after introduction of pegvisomant in a lanreotide-resistant acromegalic patient.
Fendri S; Karaca P; Tiev E; Buchfelder M; Lalau JD
Ann Endocrinol (Paris); 2013 Feb; 74(1):49-52. PubMed ID: 23337021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
